Clinical Trial Update: Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC)

View source ↗

Summary

A completed clinical trial evaluated mesothelin as a biomarker for the clinical management of esophageal adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Esophageal Cancer

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Esophageal Cancer, Adenocarcinoma | Status: COMPLETED